Home >Research Technology Management>Technology for Licensing
Anti-infective compounds (Tuberculosis APPN)
- Chinese Patent Issued: ZL200980128440.2
- US Patent Issued: 8785452
Priscille Brodin, Jaeseung Kim
Stage of Development
The present invention relates to small molecule compounds, 4H-pyrido [1, 2-a] pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
Tuberculosis (TB) is one of the most widespread disease in the world, killing approximately 1 million every year. Current therapeutic drugs for TB takes long to cure and can be toxic. There is no cure for resistant TB. The new therapeutic drugs for multi-resistant TB will save millions of lives and bring revenue of 400 billion won every year. These compounds are the novel drug candidates to treat TB.
The applications for this invention went national phase of international application PCT/EP2009/004379, filed on Jun. 17, 2009; which claims the benefit of US Provisional Application No. 61/132,285, filed on Jun. 17, 2008. The applications were filed in Australia, Canada, US, Europe, Korea, Japan, China, Brazil, India and in Hong Kong. The China and US patent application were issued on Jun 4, 2014 and July 22, 2014 respectively.